お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
市場調査レポート
商品コード
966793

マイボーム腺機能不全 (MGD) - 疫学考察:2030年

Meibomian Gland Dysfunction - Epidemiology Insight - 2030

出版日: 受注生産 | 発行: DelveInsight Business Research LLP | ページ情報: 英文 100 Pages | 納期: 約10営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.84円
マイボーム腺機能不全 (MGD) - 疫学考察:2030年
出版日: 受注生産
発行: DelveInsight Business Research LLP
ページ情報: 英文 100 Pages
納期: 約10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、マイボーム腺機能不全 (MGD) について調査分析し、過去・将来の疫学、米国・欧州5ヶ国 (ドイツ、スペイン、イタリア、フランス、英国) ・日本の市場動向に焦点を当てて、治療アルゴリズム・治療ガイドライン、疫学シナリオについて、体系的な情報を提供しています。

目次

第1章 主要考察

第2章 マイボーム腺機能不全 (MGD) のエグゼクティブサマリー

第3章 マイボーム腺機能不全 (MGD) :疾患の背景と概要

  • イントロダクション
  • 兆候と症状
  • 病態生理
  • 危険因子
  • 診断

第4章 ペイシェントジャーニー

第5章 疫学と患者集団

  • 疫学の主な調査結果
  • 前提条件と根拠:主要7ヶ国
  • 疫学シナリオ:主要7ヶ国
  • 米国の疫学
  • 欧州5ヶ国の国別疫学
  • 日本の疫学

第6章 治療アルゴリズム、現在の治療、医療行為

  • マイボーム腺機能不全 (MGD) の治療と管理
  • マイボーム腺機能不全 (MGD) の治療アルゴリズム

第7章 KOLの見解

第8章 アンメットニーズ

第9章 付録

第10章 DelveInsightのサービス内容

第11章 免責事項

第12章 DelveInsightについて

図表

List of Tables

  • Table 1: Meibomian Gland Dysfunction Epidemiology in 7MM (2017-2030)
  • Table 2: Meibomian Gland Dysfunction Diagnosed and Treatable Cases in 7MM (2017-2030)
  • Table 3: Meibomian Gland Dysfunction Epidemiology in the United States (2017-2030)
  • Table 4: Meibomian Gland Dysfunction Diagnosed and Treatable Cases in the United States (2017-2030)
  • Table 5: Meibomian Gland Dysfunction Epidemiology in Germany (2017-2030)
  • Table 6: Meibomian Gland Dysfunction Diagnosed and Treatable Cases in Germany (2017-2030)
  • Table 7: Meibomian Gland Dysfunction Epidemiology in France (2017-2030)
  • Table 8: Meibomian Gland Dysfunction Diagnosed and Treatable Cases in France (2017-2030)
  • Table 9: Meibomian Gland Dysfunction Epidemiology in Italy (2017-2030)
  • Table 10: Meibomian Gland Dysfunction Diagnosed and Treatable Cases in Italy (2017-2030)
  • Table 11: Meibomian Gland Dysfunction Epidemiology in Spain (2017-2030)
  • Table 12: Meibomian Gland Dysfunction Diagnosed and Treatable Cases in Spain (2017-2030)
  • Table 13: Meibomian Gland Dysfunction Epidemiology in the United Kingdom (2017-2030)
  • Table 14: Meibomian Gland Dysfunction Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
  • Table 15: Meibomian Gland Dysfunction Epidemiology in Japan (2017-2030)
  • Table 16: Meibomian Gland Dysfunction Diagnosed and Treatable Cases in Japan (2017-2030)

List of Figures

  • Figure 1: Meibomian Gland Dysfunction Epidemiology in 7MM (2017-2030)
  • Figure 2: Meibomian Gland Dysfunction Diagnosed and Treatable Cases in 7MM (2017-2030)
  • Figure 3: Meibomian Gland Dysfunction Epidemiology in the United States (2017-2030)
  • Figure 4: Meibomian Gland Dysfunction Diagnosed and Treatable Cases in the United States (2017-2030)
  • Figure 5: Meibomian Gland Dysfunction Epidemiology in Germany (2017-2030)
  • Figure 6: Meibomian Gland Dysfunction Diagnosed and Treatable Cases in Germany (2017-2030)
  • Figure 7: Meibomian Gland Dysfunction Epidemiology in France (2017-2030)
  • Figure 8: Meibomian Gland Dysfunction Diagnosed and Treatable Cases in France (2017-2030)
  • Figure 9: Meibomian Gland Dysfunction Epidemiology in Italy (2017-2030)
  • Figure 10: Meibomian Gland Dysfunction Diagnosed and Treatable Cases in Italy (2017-2030)
  • Figure 11: Meibomian Gland Dysfunction Epidemiology in Spain (2017-2030)
  • Figure 12: Meibomian Gland Dysfunction Diagnosed and Treatable Cases in Spain (2017-2030)
  • Figure 13: Meibomian Gland Dysfunction Epidemiology in the United Kingdom (2017-2030)
  • Figure 14: Meibomian Gland Dysfunction Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
  • Figure 15: Meibomian Gland Dysfunction Epidemiology in Japan (2017-2030)
  • Figure 16: Meibomian Gland Dysfunction Diagnosed and Treatable Cases in Japan (2017-2030)

The table of contents is not exhaustive; will be provided in the final report

目次
Product Code: DIEI1068

DelveInsight's 'Meibomian Gland Dysfunction - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Meibomian Gland Dysfunction epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Meibomian Gland Dysfunction Understanding

The DelveInsight Meibomian Gland Dysfunction epidemiology report gives a thorough understanding of the Meibomian Gland Dysfunction by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Meibomian Gland Dysfunction in the US, Europe, and Japan. The report covers the detailed information of the Meibomian Gland Dysfunction epidemiology scenario in seven major countries (US, EU5, and Japan).

Meibomian Gland Dysfunction Epidemiology Perspective by DelveInsight

The Meibomian Gland Dysfunction epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Meibomian Gland Dysfunction epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Meibomian Gland Dysfunction epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Meibomian Gland Dysfunction Detailed Epidemiology Segmentation

The Meibomian Gland Dysfunction epidemiology covered in the report provides historical as well as forecasted Meibomian Gland Dysfunction epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

The DelveInsight Meibomian Gland Dysfunction report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report:

  • The Meibomian Gland Dysfunction report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Meibomian Gland Dysfunction Epidemiology Report and Model provide an overview of the risk factors and global trends of Meibomian Gland Dysfunction in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Meibomian Gland Dysfunction in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Meibomian Gland Dysfunction
  • The report provides the segmentation of the Meibomian Gland Dysfunction epidemiology

Report Highlights:

  • 11-Year Forecast of Meibomian Gland Dysfunction epidemiology
  • 7MM Coverage
  • Total Cases of Meibomian Gland Dysfunction
  • Total Cases of Meibomian Gland Dysfunction according to segmentation
  • Diagnosed cases of Meibomian Gland Dysfunction

KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Meibomian Gland Dysfunction?
  • What are the key findings pertaining to the Meibomian Gland Dysfunction epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Meibomian Gland Dysfunction across the 7MM during the forecast period (2017-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden and unmet needs of the Meibomian Gland Dysfunction?
  • What are the currently available treatments of Meibomian Gland Dysfunction?

Reasons to buy:

  • The Meibomian Gland Dysfunction Epidemiology report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the global Meibomian Gland Dysfunction market
  • Quantify patient populations in the global Meibomian Gland Dysfunction market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Meibomian Gland Dysfunction therapeutics in each of the markets covered
  • Understand the magnitude of Meibomian Gland Dysfunction population by its epidemiology
  • The Meibomian Gland Dysfunction Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Table of Contents

1. Key Insights

2. Executive Summary of Meibomian Gland Dysfunction

3. Meibomian Gland Dysfunction : Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Sign and Symptoms
  • 3.3. Pathophysiology
  • 3.4. Risk Factors
  • 3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

  • 5.1. Epidemiology Key Findings
  • 5.2. Assumptions and Rationale: 7MM
  • 5.3. Epidemiology Scenario: 7MM
    • 5.3.1. Meibomian Gland Dysfunction Epidemiology Scenario in the 7MM (2017- 2030)
  • 5.4. United States Epidemiology
    • 5.4.1. Meibomian Gland Dysfunction Epidemiology Scenario in the United States (2017- 2030)
  • 5.5. EU-5 Country-wise Epidemiology
    • 5.5.1. Germany Epidemiology
      • 5.5.1.1. Meibomian Gland Dysfunction Epidemiology Scenario in Germany (2017- 2030)
    • 5.5.2. France Epidemiology
      • 5.5.2.1. Meibomian Gland Dysfunction Epidemiology Scenario in France (2017- 2030)
    • 5.5.3. Italy Epidemiology
      • 5.5.3.1. Meibomian Gland Dysfunction Epidemiology Scenario in Italy (2017- 2030)
    • 5.5.4. Spain Epidemiology
      • 5.5.4.1. Meibomian Gland Dysfunction Epidemiology Scenario in Spain (2017- 2030)
    • 5.5.5. United Kingdom Epidemiology
      • 5.5.5.1. Meibomian Gland Dysfunction Epidemiology Scenario in the United Kingdom (2017-2030)
  • 5.6. Japan Epidemiology
    • 5.6.1. Meibomian Gland Dysfunction Epidemiology Scenario in Japan (2017- 2030)

6. Treatment Algorithm, Current Treatment, and Medical Practices

  • 6.1. Meibomian Gland Dysfunction Treatment and Management
  • 6.2. Meibomian Gland Dysfunction Treatment Algorithm

7. KOL Views

8. Unmet Needs

9. Appendix

  • 9.1. Bibliography
  • 9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

The table of contents is not exhaustive; will be provided in the final report

株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.